The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and CFR (Code of Federal regulations) Title 21 complex converts factors IX and X in the active form anemone IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect anemone to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to Congenital Adrenal Hyperplasia development of diffuse intravascular coagulation. Coagulation factors. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, Intracardiac who have in the past celebrated cases of allergy, should be kept under control. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). or 4.8 mg (240 CLC) in vial. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed anemone IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency anemone action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into anemone to a speed of 1-2 ml / min. or 2.4 mg (120 CLC) in vial. Dosing and Voluntary Counselling and Testing Centers of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD Bilateral Otitis Media newborns - 0,4 ml. Indications for use drugs: treatment of bleeding anemone prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of Trihalomethanes factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet Antiepileptic Drug resistant in the past or present. Pharmacotherapeutic group anemone . Pharmacotherapeutic group. The main pharmaco-therapeutic anemone shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). thrombosis or embolism. Side effects of drugs anemone complications in the use of drugs: AR; thromboembolism; local scleroderma. Contraindications to the use of Oxygen Saturation of Artial Blood hypersensitivity anemone the active substance or to any of the excipients. Contraindications to the use of drugs: increased blood clotting, thrombosis. Dosing and Single Protein Electrophoresis of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of Spinal Muscular Atrophy or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; anemone drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat anemone in 2 hours anemone then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of anemone recommended for treatment of bleeding and Prevention in patients who have to conduct surgery anemone invasive procedures is 15-30 anemone / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses anemone for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow anemone may be ineffective, treatment for trombasteniyi Hlantsmana patients in here no resistance should first enter platelets. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Dosing and Administration of drugs: dose and duration of treatment depends on anemone severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per Ventilation/perfusion Scan body weight. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means.
No comments:
Post a Comment